Given that reduction of CHTM1 levels leads to poor survival of metabolically-stressed lung cancer cells as reported here, pharmacologic or genetic targeting of CHTM1 could be a viable approach to manage this malignancy. Here, CHCHD5 is linked to lung cancer.